TG Therapeutics, Inc.
Key Metrics
- Previous Close
- $51.69
- 52-Week Range
- $26.76 – $59.30
- Market Cap
- $7.74B
- P/E (TTM)
- 18.45
- EPS (TTM)
- 2.74
- Dividend Yield
- —
Advanced Metrics
- Price/Book
- 12.29
- PEG Ratio
- 1.61
- Return on Equity
- 100.28%
- Return on Assets
- 7.28%
- Gross Margin
- 82.37%
- Operating Margin
- 9.02%
- Profit Margin
- 55.22%
- Current Ratio
- 4.27
- Debt/Equity
- 1.25
- Total Debt
- $754.44M
- Free Cash Flow
- $59.13M
- Revenue Growth
- 70.30%
- Earnings Growth
- -70.60%
- Enterprise Value
- $7.53B
Market Snapshot
About
TG Therapeutics is a biopharmaceutical company focused on developing and commercializing novel treatments for B-cell diseases, including chronic lymphocytic leukemia (CLL) and multiple sclerosis. The company markets BRIUMVI for relapsing forms of multiple sclerosis and continues advancing its pipeline of targeted immunotherapies.